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ABSTRACT
Introduction: Previous studies have suggested that
more intensive initial therapy for hypertension results
in better long-term blood pressure (BP) control. We
test this hypothesis comparing initial monotherapy
with dual therapy in the management of essential
hypertension.
Methods and analysis: The study is a prospective,
multicentre, double-blind, active-controlled trial in
patients with essential hypertension. Around 50% of
patients studied will be newly diagnosed and the
others will be known hypertensives who previously
received only monotherapy. The trial is divided into
three phases as follows: Phase 1 (Week 0–Week 16):
Randomised, parallel-group, masked assignation to
either combination or monotherapy. Phase 2 (Week
17–Week 32): Open-label combination therapy. Phase
3 (Week 33–Week 52): Open-label combination therapy
plus open-label add-on (if BP is above 140/
90 mm Hg). Hierarchical primary end points are:
a comparison of home BP (home systolic blood
pressure (HSBP)) averaged over the duration of phase
1 and 2 in the combination versus monotherapy arms.
If combination is superior in this analysis, then the
averaged mean HSBP between initial monotherapy and
initial combination therapy at the end of phase 2 will
be compared. Secondary end points include: BP
control at 1 year; the role of age, baseline renin,
sodium status, plasma volume, haemodynamic
compensation and peripheral resistance on BP control;
validation of the National Institute for Clinical
Excellence/British Hypertension Society joint guideline
algorithm; safety and tolerability of combination
therapy; and the impact of combination versus
monotherapy on left ventricular mass and aortic pulse
wave velocity. A sample size of 536 (268 in each
group) will have 90% power to detect a difference in
means of 4 mm Hg.
Ethics and dissemination: PATHWAY 1 was
approved by UK ethics (REC Reference 09/H0308/132).
Trial results will be published and all participating
subjects will be informed of the results.
Trial registration number: UKCRN 4499 and
EudraCT number 2008-007749-29 registered 27/08/
2009.
INTRODUCTION
At least 20% of patients with essential hyper-
tension do not have their blood pressure
(BP) under control despite treatment with
triple therapy.1 The hypothesis that aggres-
sive early treatment of hypertension may
prevent subsequent treatment resistance was
generated by the results of the Valsartan
Antihypertensive Long-term Use Evaluation
(VALUE)2 and the Anglo Scandinavian
Cardiac Outcomes Trial (ASCOT)3 studies.
In these studies, participants randomised to
the less effective of two treatments early in
the study ‘never caught up’ with the BP low-
ering achieved in the other group, despite
eventually receiving more drug therapy.
Furthermore, a study of dual therapy versus
monotherapy with aliskiren and amlodipine
showed that participants started on initial
dual therapy appeared always to have better
BP control than the monotherapy group.4
A plausible explanation of the ‘never catch
up’ phenomenon is that one drug given
alone initiates activation of homeostatic
mechanisms, which minimises efﬁcacy. Thus
a diuretic or calcium antagonist given alone
would lead to a rise in renin levels, effectively
antagonising the effect of the initial drug.
Given such a mechanism, one would expect
that a drug that blocked the effects of a rise
in renin would produce complementary
effects. Support for this concept comes from
Strengths and limitations of this study
▪ Randomised, double-blind, multicentre, con-
trolled clinical trial.
▪ Uses home systolic blood pressure as the
primary outcome.
▪ Powered to detect a 4 mm Hg difference in blood
pressure; so a smaller but possibly important
true difference may be missed.
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a study where measurements of thoracic ﬂuid volume
supported the occult volume expansion hypothesis as a
mediator of antihypertensive drug resistance. This study
guided increasing the diuretic dose and adjustment of
antihypertensive treatment by using thoracic bioimpe-
dance measurements, which was found to be an effective
strategy.5
Historically, initial treatment of hypertension with com-
bination therapy has been discouraged because of concern
about excessive reduction in BP, increased side effects and
the difﬁculty of attributing adverse events to one drug.
However, the US Joint National Committee guideline 8
( JNC8) guidelines have listed that a two-drug initial treat-
ment is an acceptable strategy in patients who are
20 mmHg above systolic target BP or 10 mmHg above dia-
stolic BP target or whose systolic BP is >160 mmHg or dia-
stolic >100 mm Hg.6 These and previous guidelines that
advocated similar strategies have not resulted in reports of
problems with this approach. The European guidelines
also include low-dose combination therapy as an initial
treatment option.7
Despite the currently available evidence, in reality,
initial combination therapy is not commonly used and
formal prospective studies are required to catalyse
change. A further study demonstrating improved BP
control with initial combination therapy would provide
further evidence that using widely available, inexpensive
combinations is appropriate. Our trial here, PATHWAY 1,
funded by the British Heart Foundation, aims to provide
such evidence.
METHOD
Setting
British Hypertension Society Research Network of inves-
tigators recruiting participants from both primary care
and secondary care.
Overall trial design
The study is a prospective, multicentre, active-controlled,
three-phase trial in UK patients with essential hyperten-
sion. A study schematic is shown in ﬁgure 1.
A 4-week single-blinded placebo run-in period pre-
cedes the ﬁrst active phase. This run-in determines ﬁnal
patient eligibility based on BP readings recorded during
this period. Following the placebo run-in, phase 1 rando-
mises patients to either combination therapy or mono-
therapy. Phase 2 is open-label combination therapy for
all patients with forced dose titration. Phase 3 is open-
label combination therapy for all patients with the
option of additional open-label add-on therapy to
achieve BP target (<140/90 mm Hg).
Trial medication
The two medications used alone or in combination in
the trial are losartan and hydrochlorothiazide (HCTZ).
Each patient receives active trial medication for 52 weeks
following the 4-week placebo run-in phase. Phase 1
medication is double blinded. Combination therapy
used in phase 2 and phase 3 was initially Cozaar-Comp
(100/12.5 mg and 100/25 mg); however, this was
changed to generic losartan/HCTZ in 2013.
Phase 1: Medication—weeks 0–16
Intervention: Initial combination therapy with losartan/
HCTZ. Dose titrations occur every 4 weeks (losartan/
HCTZ 50/12.5 then losartan/HCTZ 50/25 then
losartan/HCTZ 100/12.5 then losartan/HCTZ 100/25).
Active comparator: Initial monotherapy with random-
isation to either HCTZ 12.5 mg titrated to 25 mg after
4 weeks or losartan 50 mg titrated to 100 mg after 4 weeks
with crossover of HCTZ and losartan drugs at week 8.
Phase 2: Medication—weeks 17–32
All patients receive open-label combination therapy with
losartan/HCTZ 100/12.5 initially, titrated to losartan/
HCTZ 100/25 at week 24.
Phase 3: Medication—weeks 33–52
All patients receive losartan/HCTZ 100/25 with open
label add-on therapy as required. Requirement for
add-on therapy is assessed at the week 32 visit, and if
clinic systolic BP >140 mm Hg or diastolic BP >90 mm Hg
is recorded, the ﬁrst-line add-on therapy is amlodipine
5 mg. At week 38 this may be titrated to amlodipine
10 mg if BP remains uncontrolled with addition of modi-
ﬁed release doxazosin 4 mg or 8 mg, if required, at week
44 visit.
Figure 1 Study schematic.
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Recruitment and randomisation
Patient recruitment is taking place at multiple sites
across the UK. Consent will be obtained by study doctors
at each study site (see online supplementary appendix 1
for consent form). Each participant will be in the study
for 56 weeks (4-week placebo run-in followed by 52-week
active treatment). Potential participants are identiﬁed by
their general practitioner or via hypertension clinics.
Trial inclusion criteria are: (patients must meet all
inclusion criteria to be eligible)
1. Clinic BP ≥150 mm Hg (systolic) OR ≥95 mm Hg
(diastolic) after placebo run-in. Patients may be
included if the investigator anticipates BP criteria for
inclusion will be met at randomisation (ie, if BP is
likely to meet criteria after withdrawal of previous
monotherapy during placebo run-in phase).
2. Aged 18–79 years.
3. Either never-treated hypertension or received a
maximum of one antihypertensive drug class in the
previous year.
4. Male participants or female participants taking
adequate contraception such as the contraceptive
pill, an intrauterine device or who are surgically steri-
lised, or postmenopausal females.
Exclusion criteria are shown in box 1.
TRIAL PROCEDURES
BP measurements
Home BP and pulse rate will be measured using the
Microlife WatchBP Home monitor. We believe this is
one of the ﬁrst trials to use home BP as the primary
outcome measure, offering similar advantages to ambu-
latory monitoring (multiple measurements in the
absence of white-coat stimuli) without the disadvantage
of patient resistance to repeated use. Patients will be
instructed to take BP readings on the past four consecu-
tive days before each clinic visit (baseline and at weeks
4, 8, 12, 16, 24, 32, 38, 44 and 52). Patients will be asked
to measure their BP as close as possible to 8:00 and
20:00, and to take readings in triplicate, after 10 min
seated rest. The second and third readings are recorded
on a pro forma provided to each patient. The 12 read-
ings thus obtained for analysis confer near-maximal pre-
cision. All readings will also be captured automatically
by the monitor. Study medication should be taken after
morning BP readings are completed.
Clinic BP measurements are taken at each study visit, on
the patient’s Microlife monitor, and patients will have their
BP and pulse rate recorded in triplicate after 10 min seated
rest. The ﬁrst reading will be discarded and the mean
clinic readings will be the average of the last 2 readings.
Additional procedures
A 12-lead ECG is captured at the start and end of the
study. Haemodynamic measures (cardiac output, periph-
eral resistance and bioimpedance) and pulse wave ana-
lysis are captured at baseline and at weeks 8, 16, 32 and
52 in centres that have the appropriate Cardiodynamics
equipment. Plasma renin is measured at baseline and a
full biochemical series is taken at regular intervals for
safety.
COMPLIANCE, EFFICACY AND TOLERABILITY
Compliance with study medication will be assessed at the
end of the placebo run-in and at each scheduled clinic
visit postrandomisation. Assessment is by counting cap-
sules/tablets returned at each visit. To be evaluable as a
compliant participant ≥80% compliance with therapy is
required.
Patients may be withdrawn from the study if the investi-
gator feels it would be in the patient’s best interest, if the
patient demonstrates intolerance to study drug, if plasma
potassium levels are sustained at <3.0 mmol/L or
>5.9 mmol/L, if BP is uncontrolled (>200/120 mm Hg)
or if the patient develops symptomatic hypotension with
systolic BP <110 mmHg. Investigators may advance
patients with uncontrolled BP to the next study visit where
dose titration will occur. There is no option for down titra-
tion of combination therapy during phase 2. Therefore,
patients unable to tolerate losartan/HCTZ 100/25 mg will
be withdrawn.
FOLLOW-UP
Primary end point
The ﬁrst primary end point for PATHWAY 1 is the mean
of all HSBP readings taken during phase 1 and 2 com-
paring the combination therapy versus the monotherapy
arms. If (and only if) the mean systolic BP in phase 1
and 2 is signiﬁcantly better in the combination therapy
arm then the second primary end point will be the
change in mean HSBP for the group treated initially
with monotherapy compared to the group treated ini-
tially with combination therapy at the end of phase
2. Readings used for this calculation will be from the
past 3 days of placebo run-in compared to the past
3 days of phase 2 (week 32).
Secondary end points and substudy
Secondary end points are detailed in box 2. In addition
there will be a substudy in three sites using cardiac MRI
to compare the change in left ventricular mass and
aortic pulse wave velocity (arterial stiffness) between
initial combination and initial monotherapy groups for
which consent is sought separately.
Data handling and record keeping
Study data is recorded and stored via remote data entry
into a web-based electronic case report form (eCRF)
developed and maintained for the study by the Robertson
Centre for Biostatistics, University of Glasgow, Level 11,
Boyd Orr Building, University Avenue, Glasgow, G12 8QQ.
eCRF data are anonymous and identify study partici-
pants by their assigned study numbers only.
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Investigator training
All investigators were trained in good clinical practice
and received trial-speciﬁc training. The trial was moni-
tored by the sponsor. Regular meetings were held to
discuss trial quality issues and progress. A full list of
study sites is available at: https://www.clinicaltrials.gov/
ct2/show/NCT00994617?term=pathway-1&rank=1
Adverse events and serious adverse events
All observed or volunteered adverse events considered
related to treatment will be recorded on the adverse
events page of the eCRF. Study staff will pursue and
obtain information adequate to conﬁrm whether the
event meets the criteria for classiﬁcation as a serious
adverse event. An event will be deemed serious if it
results in death, is life-threatening, requires hospitalisa-
tion, results in persistent or signiﬁcant disability/
incapacity, is a congenital anomaly or birth defect or is
another medically important event. Adverse events will be
classiﬁed according to seriousness, severity (mild, moder-
ate or severe), causal relationship (certain, probably, pos-
sible, unlikely, unrelated) and expectedness. Suspected
unexpected serious adverse drug reactions (SUSARs) are
not considered likely in this trial as there have been many
years of experience with each of the trial drugs. All poten-
tial SUSARs are subject to expedited reporting.
DATA ANALYSIS AND STATISTICAL METHODS
Sample size
A sample size of 268 in each group will have 90% power
to detect a difference in means of 4 mm Hg HSBP,
assuming a common SD of 12 mm Hg using a two group
t test with α=0.01.
Box 1 Exclusion criteria
Patients will be excluded for ANY ONE of the following reasons
1. Clinic systolic blood pressure >200 mm Hg or diastolic blood pressure >120 mm Hg, with principal investigator discretion to over-ride if
home blood pressure (HBP) measurements are lower.
2. Secondary or accelerated phase hypertension.
3. Estimated-glomerular filtration rate <45 mLs/min.
4. Contraindication or previous intolerance to any trial therapy.
5. Failure to record required HBP readings during placebo run-in.
6. Significant comorbidity (investigator opinion but to include alcoholism, terminal illness, documented non-attendance at clinics etc).
7. Diabetes type 1.
8. Plasma K+ outside normal range on two successive measurements during screening.
9. Requirement for treatment with ≥2 drugs (which can be a CCB and/or {ACEi OR ARB OR direct renin inhibitor OR β-blocker}) in order
to reduce blood pressure to ≤180/120 mm Hg.
10. Requirement for diuretic therapy (other than for hypertension).
11. Requirement for ACE inhibitor (or angiotensin II receptor blocker) therapy (other than for hypertension).
12. Absolute contraindications to any of the study drugs (listed on their data-sheet).
13. Current therapy for cancer.
14. Anticipation of change in medical status during course of trial (eg, planned surgical intervention requiring >2 weeks convalescence,
actual or planned pregnancy).
15. Inability to give informed consent.
16. Participation in a clinical study involving an investigational drug or device within 4 weeks of screening.
17. Any concomitant condition that, in the opinion of the investigator, may adversely affect the safety and/or efficacy of the study drug or
severely limit the participant’s lifespan or ability to complete the study (eg, alcohol or drug abuse, disabling or terminal illness, mental
disorders).
18. Treatment with any of the following prohibited medications
A. Oral corticosteroids within 3 months of screening. Treatment with systemic corticosteroids is also prohibited during study
participation.
B. Chronic stable or unstable use of non-steroidal anti-inflammatory drugs (NSAIDs) other than acetylsalicylic acid is prohibited.
Chronic use is defined as >3 consecutive or non-consecutive days of treatment per week. In addition, the intermittent use of
NSAIDs is strongly discouraged throughout the duration of this study. If intermittent treatment is required, NSAIDs must not be
used for more than a total of 2 days. For all participants requiring analgesic or antipyretic agents, the use of paracetamol is
recommended during study participation.
C. The use of short-acting oral nitrates (eg, sublingual nitroglycerin) is permitted; however, participants should not take short-acting
oral nitrates within 4 h of screening or any subsequent study visit.
D. The use of long-acting oral nitrates (eg, Isordil) is permitted; however, the dose must be stable for at least 2 weeks prior to
screening and randomisation.
E. The use of sympathomimetic decongestants is permitted; however, not within 1 day prior to any clinic visit/BP assessment.
F. The use of theophylline is permitted; however, the dose must be stable for at least 4 weeks prior to screening and throughout
study participation.
G. The use of phosphodiesterase (PDE) type V inhibitors is permitted; however, participants must refrain from taking these medica-
tions within 1 day of screening or any subsequent study visit.
H. The use of α-blockers is not permitted—with the exception of afluzosin and tamsulosin for prostatic symptoms.
4 MacDonald TM, et al. BMJ Open 2015;5:e007645. doi:10.1136/bmjopen-2015-007645
Open Access
Randomisation
Study participants are randomised 1:1 to either initial
combination or initial monotherapy using an Interactive
Voice Recognition System located at the Robertson
Centre for Biostatistics at Glasgow University. The aim is
to achieve a 50:50 balance between never treated and
previously treated patients. Therefore, recruitment to
one of these groups (never treated, or previously
treated) may be stopped temporarily, or permanently, if
the chief investigator and data management centre con-
sider it necessary in order to achieve a ﬁnal recruitment
that does not exceed a 60:40 proportion of either group.
Randomisation will continue until 600 participants have
been recruited (to allow for dropouts) or until 536 eva-
luable participants have completed the study.
Database lock
Since the study is double-blind, all investigators remain
blinded until database lock. Un-blinding is only permis-
sible if required for an urgent patient-safety issue
Analysis
There will be hierarchical coprimary end points. An ana-
lysis will be performed ﬁrst to compare the mean HSBP
readings in phase 1 and 2 between combination therapy
and monotherapy. If averaged combination therapy is
superior to monotherapy, a second primary analysis will
compare the mean HSBP at the end of phase 2 (namely
visit 8 at week 32) between initial combination and
monotherapy. The analyses will adjust for baseline cov-
ariates (demographics, baseline HSBP and never vs pre-
viously treated). Last reading carried forward will be
used in the intention to treat analysis in those partici-
pants who fail to complete the full study for whatever
reason.
Secondary analyses will compare: change in HSBP at
8, 16 (end of phase 1) and 52 weeks (end of phase 3);
change in clinic SBP at these times and end of phase 2;
responder rates at the end of phase 1, 2 and 3 (deﬁned
as HSBP <135/<85, and/or clinic <140/<90, and/or fall
in SBP ≥10 mm Hg); withdrawals due to adverse events;
the number of drugs being prescribed at the end of
phase 3; a Kaplan-Meier analysis for events, namely
either addition of third drug or withdrawal due to an
adverse event; haemodynamic variables and pulse wave
analysis—these will be analysed in the same way as BP,
with and without correction for BP. The extent to which
plasma renin and haemodynamic variables explain vari-
ation in response between and within treatment groups
will be investigated for both primary and secondary
outcomes.
A full statistical analysis plan is available from the chief
investigator MJB.
ETHICAL AND OTHER APPROVALS
The trial has been approved by the Cambridgeshire 2
Research Ethics Committee of the NHS National
Research Ethics Service (number 091/H0308/1132), and
the Medicines and Healthcare products Regulatory
Agency (EudraCT number: 2008-007749-29). The trial is
performed in line with Good Clinical Practice guidelines.
A trial steering committee composed of the investigators
and authors of this protocol were responsible for design-
ing the study and are responsible for setting up, evaluat-
ing and reporting results of the trial and will consider
requests for access to trial data and analyses if requested.
Protocol amendments
All protocol amendments will be approved by the
sponsor, research ethics committees and the Medicines
Healthcare Regulatory Agency Clinical Trials Unit.
Study sponsorship: monitoring, audit, quality control and
quality assurance
The trial is sponsored by the University of Cambridge
and Cambridge University Hospitals National Health
Service (NHS) Foundation Trust. Trial investigators will
permit authorised third parties access to the trial site
and medical records relating to trial participants. This
will include, but not necessarily be restricted to, access
for trial-related monitoring, audits, Ethics Committee
review and regulatory inspections.
Box 2 Secondary end points
1. A comparison of the proportion of patients who drop out of
the trial at any stage after randomisation or who require add-
itional antihypertensive drug therapy in phase 3 of the trial
between the initial monotherapy and combination therapy
limbs. (Note a separate count of those who drop out because
blood pressure (BP) is reduced too avidly will be noted).
2. A comparison of the change in BP from baseline to the end of
phase 3 between the initial monotherapy and combination
therapy limbs.
3. A comparison of the change in thoracic bioimpedance and
arterial stiffness from baseline to the end of phase 1 and then
separately to the end of phase 2 between the initial monother-
apy and combination therapy limbs and how this predicts the
primary end point.
4. An analysis of how the baseline covariates of age, gender,
renin mass, weight, height, thoracic bioimpedance and arterial
stiffness prior treatment of BP etc. predict the differences in
Δsystolic BP between the initial monotherapy and combination
therapy limbs.
5. A comparison of the predictors of BP fall with each initial
monotherapy in phase 1 is predicted by age (particularly ≤55
or >55 years), gender, renin mass, weight, height, thoracic
bioimpedance and arterial stiffness, prior treatment of BP, etc.
6. Analyses of relationships between genetic factors and pharma-
codynamic responses. (Pharmacogenetic research is likely to
continue following completion of this study, and will not be
reported as part of the main study report).
7. A comparison of the change in left ventricular mass (cardiac
hypertrophy) and aortic pulse wave velocity (arterial stiffness)
from baseline to the end of phase 3 between the initial mono-
therapy and combination therapy groups.
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Dissemination
The results of the trial will be published in a peer-
reviewed scientiﬁc journal. All participants will be
informed about the trial results and the treatment allo-
cation arm they were allocated.
ASSOCIATED PROJECTS
This study (PATHWAY-1) is one of three complementary
studies in a BHF-funded programme which will investi-
gate optimal treatment for patients with drug-resistant
hypertension. PATHWAY-2 will recruit patients with more
severe hypertension than either PATHWAY-1 or
PATHWAY-3, which is a comparison of a potassium
retaining plus a thiazide diuretic with either alone, for
their effects on BP and glucose tolerance.
DISCUSSION
Current practice in hypertension management uses a
stepped care approach with initial monotherapy that is
added on to, according to the results of subsequent
blood pressure measurement. The concern is that lower-
ing blood pressure by one drug triggers adaptive
responses in the patient that, if triggered in the early
stages of hypertension management, will impair further
attempts to achieve target blood pressure. This study
tests whether initial combination therapy with two drugs
that are complementary in action is superior to the
current stepped-care approach; we are using widely avail-
able, generic drugs at optimal doses. The primary end
point uses home BP monitoring which will give a more
accurate representation of the patients’ true BP com-
pared to using clinic readings alone. In phase one, half
the patients go through a crossover trial-within-a trial; so
we will have excellent prospective data to evaluate
whether angiotensin II receptor blocker (ARB) or diur-
etic is more effective, respectively, in the younger and
older patients and whether baseline renin is more or less
predictive than age. We also have haemodynamic indices,
including peripheral resistance, cardiac output, thoracic
impedance and arterial function, in order to determine
whether increases in any parameter underpin the postu-
lated compensatory responses to monotherapy. These
measurements will also help to establish whether—for
instance—peripheral resistance is higher in patients
responding better to ARB than diuretic, and whether thor-
acic impedance (a measure of body ﬂuid) a better pre-
dictor of response to diuretic. The relatively long duration
of the study also allows for assessment of those patients
who are deemed to have resistant hypertension in phase 3.
Conﬁrmation that patients starting with monotherapy
‘never catch up’ with patients starting on combination
therapy would have a major impact on hypertension
treatment practice; possibly more than any previous
study in hypertension.
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